



OMICXSCREEN™ FROM OMICXHEALTH

Catch Cancer Early. Save Lives.

Multi-Cancer Early Detection (MCED) powered by cfDNA + AI/ML

Liver Cancer Early Detection. Independently Validated


Multi-Cancer Early Detection Ready Platform

Single Blood Draw Tests for Over a Dozen Cancers

How OmicXScreen™ Works

One DNA extraction across the genome.

Multiple complementary cancer signals analyzed for high accuracy in early-stage cancer detection.



WHY IT MATTERS

Early detection matters because that is when cancer is most curable. And most affordable to treat.

90% vs 14%

5-yr survival across all cancers: localized vs. distant stage

\$6.5 Trillion

in economic value from cancer screening & early detection (1996–2020)

Sources: NCI SEER, all cancer sites combined (2008–2014 diagnoses); BMC Health Services Research, 2023

Why OmicXHealth

🎯 Multiple Signals = More Accuracy

- Multiple orthogonal cancer signals (methylation, fragmentomics, copy number alterations) from a single WGBS run
- Competitors have fewer signals. Methylation only (targeted panel) or fragmentomics/CNA (low depth WGS)
- Transparent, signal-level results. Not a black-box score

⚡ Software-Defined = Faster Innovation

- All proprietary IP lives in the software layer
- New cancer signals ship as a model update. Not a new wet-lab assay

🏆 Patent-Pending & Independently Validated

- Patent-pending method enables cost-effective extraction of multiple signals from a single, moderate-depth WGBS run
- Blinded, independent liver cancer validation underway at UT Southwestern
- NCI SBIR-backed

☁ Capital-Efficient Go-To-Market

- No expensive lab infrastructure buildout required
- Off-the-shelf reagents and sequencing. All proprietary value lives in the software layer
- After regulatory approval, test can be licensed to large labs for scale. No owned lab required, even at high volume



Join the Interest List

Sign up for updates and Early Access to the test when it becomes commercially available



info@omicxhealth.com



omicxhealth.com